 GAITHERSBURG, Md., Nov. 08, 2021 GLOBE NEWSWIRE -- NexImmune, Inc. Nasdaq: NEXI, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open. 